Novocure denied FDA approval for metastatic cancer treatment
The FDA had uncertainty about the degree of clinical benefit for Novocure’s treatment of brain metastases, the company said.
The FDA had uncertainty about the degree of clinical benefit for Novocure’s treatment of brain metastases, the company said.